Research

We are wholly dedicated to acquiring a better understanding of the mechanisms of cancer drug resistance in order to vastly improve patient survival and quality of life.

Research Topics

Identifying Vulnerability of Cancer Cells

Discovery of cancer-selective vulnerabilities and therapeutic dependencies for selectively eliminating virulent cancer cells.

Epigenetic Mechanism for Immune Evasion

Understanding how malignant cells epigenetically remodel immune recognition and evade tumor immunity.

Novel Oncogenic Metabolites

Discovering metabolites and metabolic states that support cancer progression and therapy resistance.

Novel Immunotherapy Modalities

Exploring translational strategies including TIL-based therapy and cancer vaccines.

Previous Projects

Epigenetic Repression of STING by MYC

MYC-mediated epigenetic repression of STING promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer.

MYC/MCL1 and Chemotherapy-Resistant Cancer Stem Cells

MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation.

PRR11-Driven Antiestrogen Resistance

PRR11 overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.

Approaches

We seek to solve problems raised by patient-derived clinical information through comprehensive interpretation of omics data combined with results from molecular biology assays.

Omics & Bio-Big Data

Transcriptomic, genomic, and patient-data-driven analysis for biomarker discovery.

Molecular & Cellular Biology

Mechanistic validation using cancer models, perturbation experiments, and functional assays.

Translational Cancer Biology

Connecting molecular mechanisms to therapeutic response, resistance, and patient-relevant hypotheses.